The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.

Autor: Sartori G; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland., Tarantelli C; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland., Spriano F; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland., Gaudio E; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland., Cascione L; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Mascia M; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland., Barreca M; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.; Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy., Arribas AJ; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Licenziato L; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.; Department of Veterinary Sciences, University of Turin, Turin, Italy., Golino G; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland., Ferragamo A; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland., Pileri S; Division of Diagnostic Haematopathology, European Institute of Oncology, Milan, Italy., Damia G; Laboratory of Molecular Pharmacology, Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy., Zucca E; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland., Stathis A; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.; Faculty of Biomedical Sciences, USI, Lugano, Switzerland., Politz O; Bayer AG, Pharmaceuticals, Research & Development, Berlin, Germany., Wengner AM; Bayer AG, Pharmaceuticals, Research & Development, Berlin, Germany., Bertoni F; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Jan; Vol. 204 (1), pp. 191-205. Date of Electronic Publication: 2023 Nov 27.

Overview of BH3 mimetics in ovarian cancer.

Autor: Del Bufalo D; Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, Via E. Chianesi 53, 00144 Rome, Italy. Electronic address: donatella.delbufalo@ifo.it., Damia G; Laboratory of Gynecological Preclinical Oncology, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via M. Negri 2, 20156 Milan, Italy. Electronic address: giovanna.damia@marionegri.it.

Publikováno v: Cancer treatment reviews [Cancer Treat Rev] 2024 Sep; Vol. 129, pp. 102771. Date of Electronic Publication: 2024 May 24.

Synthesis of α-fluorocinnamate derivatives as novel cathepsin S inhibitors with in vitro antiproliferative activity against pancreatic cancer cells.

Autor: Citarella A; Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milano, Italy. Electronic address: andrea.citarella@unimi.it., Petrella S; Laboratory of Gynecological Preclinical Oncology, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via M. Negri 2, 20156 Milan, Italy., Moi D; Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milano, Italy., Dimasi A; Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milano, Italy., Braga T; Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milano, Italy., Ruberto L; Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milano, Italy., Pieraccini S; Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milano, Italy., Sironi M; Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milano, Italy., Micale N; Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres 31, I-98166 Messina, Italy., Schirmeister T; Department of Medicinal Chemistry, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany., Damia G; Laboratory of Gynecological Preclinical Oncology, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via M. Negri 2, 20156 Milan, Italy., Fasano V; Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milano, Italy., Silvani A; Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milano, Italy., Giannini C; Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milano, Italy., Passarella D; Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milano, Italy.

Publikováno v: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2024 Dec 01; Vol. 115, pp. 117987. Date of Electronic Publication: 2024 Nov 05.

Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas.

Autor: Chiappa M; Laboratory of Preclinical Gynecological Oncology, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy., Decio A; Laboratory of Cancer Metastasis Therapeutics, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy., Guarrera L; Computational Oncology Unit, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy., Mengoli I; Laboratory of Preclinical Gynecological Oncology, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy., Karki A; R&D Department, Cardiff Oncology, San Diego, CA, USA., Yemane D; R&D Department, Cardiff Oncology, San Diego, CA, USA., Ghilardi C; Laboratory of Cancer Metastasis Therapeutics, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy., Scanziani E; Department of Veterinary Medicine and Animal Sciences (DIVAS), University of Milan, Lodi Campus, Italy.; Mouse and Animal Pathology Lab (MAPLab), UniMi Foundation, Milan, Italy., Canesi S; Department of Veterinary Medicine and Animal Sciences (DIVAS), University of Milan, Lodi Campus, Italy.; Mouse and Animal Pathology Lab (MAPLab), UniMi Foundation, Milan, Italy., Barbera MC; Computational Oncology Unit, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy., Craparotta I; Computational Oncology Unit, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy., Bolis M; Computational Oncology Unit, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy., Fruscio R; Clinic of Obstetrics and Gynecology, Department of Medicine and Surgery, San Gerardo Hospital, University of Milan Bicocca, Monza, Italy., Grasselli C; Immuno-Pharmacology Unit, Department of Oncology, Mario Negri Institute for Pharmacological Research (IRCCS), Milan, Italy., Ceruti T; Laboratory of Laboratory of Cancer Pharmacology, Experimental Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy., Zucchetti M; Laboratory of Laboratory of Cancer Pharmacology, Experimental Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy., Patterson JC; Center for Precision Cancer Medicine, David H. Koch Institute for Integrative Cancer Research, Departments of Biology and Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Lu RA; Center for Precision Cancer Medicine, David H. Koch Institute for Integrative Cancer Research, Departments of Biology and Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Yaffe MB; Center for Precision Cancer Medicine, David H. Koch Institute for Integrative Cancer Research, Departments of Biology and Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Ridinger M; R&D Department, Cardiff Oncology, San Diego, CA, USA., Damia G; Laboratory of Preclinical Gynecological Oncology, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. giovanna.damia@marionegri.it., Guffanti F; Laboratory of Preclinical Gynecological Oncology, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Publikováno v: Cell death & disease [Cell Death Dis] 2024 Jul 22; Vol. 15 (7), pp. 521. Date of Electronic Publication: 2024 Jul 22.

Different Patterns of Platinum Resistance in Ovarian Cancer Cells with Homologous Recombination Proficient and Deficient Background.

Autor: Chiappa M; Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via M. Negri 2, 20156 Milan, Italy., Guffanti F; Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via M. Negri 2, 20156 Milan, Italy., Grasselli C; Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via M. Negri 2, 20156 Milan, Italy., Panini N; Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via M. Negri 2, 20156 Milan, Italy., Corbelli A; Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via M. Negri 2, 20156 Milan, Italy., Fiordaliso F; Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via M. Negri 2, 20156 Milan, Italy., Damia G; Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via M. Negri 2, 20156 Milan, Italy.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2024 Mar 06; Vol. 25 (5). Date of Electronic Publication: 2024 Mar 06.